With a grant of DKK 2.6m (USD 395,541) from the Michael J. Fox Foundation, Lundbeck is ready to take the development of the world’s first test for Parkinson’s disease to the next level, the company informs MedWatch in an email.
Three years ago, Lundbeck began the journey to create the first validated biomarker test for Parkinson’s disease, focused on detecting the build-up of minute amounts of the protein alpha-synuclein. This is measured by sampling cerebrospinal fluid. In a collaboration with academic experts, Lundbeck has now developed a test that can detect with 90 percent accuracy whether a person has aggregated the protein, indicative of Parkinson’s, in their cerebrospinal fluid.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Senior Chemical Safety Advisor 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Account Manager 
Senior Project Manager (GMP - Life Science) 
Scientific Writer 
Clinical Trial Administrator 
Senior Manager, Clinical Trial Budget 
Key Account Manager, Europe and Asia 
Nordic Medical Affairs Manager 
Biomarker Operations Lead 
Clinical Trial Manager for development of in vitro diagnostics 
Communications Consultant 
Chemist for Incoming Materials in QC Department 
Production Director 
Client Talent Acquisition Specialist 
Director for innovative pre-clinical testing unit